Elesclomol (STA-4783)

Catalog No.S1052

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Cited by 7 Publications

Cell, 2017, 168(1-2):86-100

PubMed: 27916275 ( click the link to review the publication )

Osteoporos Int, 2018, 29(8):1917-1926

PubMed: 29860665 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):635-646

PubMed: 29917168 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 85:166-174

PubMed: 28259749 ( click the link to review the publication )

Int J Radiat Biol, 2017, 93(2):194-203

PubMed: 27600766 ( click the link to review the publication )

Oncotarget, 2016, 10.18632/oncotarget.10921

PubMed: 27486766 ( click the link to review the publication )

BMC Genomics, 2014, 15(1):263

PubMed: 24708151 ( click the link to review the publication )

4 Customer Reviews

BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.
Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Targets

HSP70 ^[1]
(Cell-free assay)

In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. ^[1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. ^[2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NOS-1 cell	Ml\OS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MUDJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJFMvPj[nLUC1JO69VQ>?	NGLTemdUSU6JRWK=
CAL-51 cell	M2SzdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3K5NWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjZibl2=	M{PYW3NCVkeHUh?=
ABC-1 cell	NHHEVZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M{PQWGlvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3PSCwTR?=	NFLsNWNUSU6JRWK=
A2780 cell	NVHRZWs3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD61PVQhdk1?	MU\TRW5ITVJ?
ES1 cell	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmfzTY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLke0PUBvVQ>?	Mn;lV2FPT0WU
HUTU-80 cell	NE\CNWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXPJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc6OSCwTR?=	Mn75V2FPT0WU
NCI-H292 cell	NF3sc4lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1H2eGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh6NjDuUS=>	MWPTRW5ITVJ?
NB69 cell	NG\C[2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1jWS2lvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNlIhdk1?	M4TYVnNCVkeHUh?=
ES8 cell	M373TGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MUjJcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwM{Kgcm0>	NYPST3BGW0GQR1XS
BCPAP cell	NETDSJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MoPaTY5pcWKrdHnvckBw\iCqdX3hckBDS1CDUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuN\|Qhdk1?	NVHUNHZ{W0GQR1XS
T-24 cell	M2Hyd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1S5emlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOVUhdk1?	NVK5c3J[W0GQR1XS
EW-16 cell	NWPW[\|JqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M33qbmlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYyKG6P	Mo\LV2FPT0WU
OVCAR-5 cell	Mk\MS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NEDjSGJKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjh\|IH7N	M{D0bHNCVkeHUh?=
SF126 cell	NHra[41Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MVjJcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT65OUBvVQ>?	NWThPZhVW0GQR1XS
KP-4 cell	MlHiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M2HFRmlvcGmkaYTpc44hd2ZiaIXtZY4hU1BvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNVchdk1?	MkjmV2FPT0WU
GAMG cell	M{TaSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M2rvWGlvcGmkaYTpc44hd2ZiaIXtZY4hT0GPRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuOVEhdk1?	MUHTRW5ITVJ?
HOS cell	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MUfJcohq[mm2aX;uJI9nKGi3bXHuJGhQWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwNUOgcm0>	NULqRWxUW0GQR1XS
CHL-1 cell	NFPOU4xIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NGrMTI5KdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45OSCwTR?=	M1\iTXNCVkeHUh?=
AGS cell	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHi5TpRKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPFYhdk1?	NHHRT5BUSU6JRWK=
MDA-MB-157 cell	MlOwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXj4U2lHUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOTV5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj65NkBvVQ>?	NH[xfm5USU6JRWK=
HSC-3 cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MkXKTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuNFIhdk1?	NEnsOYFUSU6JRWK=
CAL-72 cell	NIHZNVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NGnHWFRKdmirYnn0bY9vKG:oIHj1cYFvKEODTD23NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODJibl2=	MoTmV2FPT0WU
NBsusSR cell	M4D1XGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NEfZbJFKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjF\|IH7N	NIrad5lUSU6JRWK=
ES7 cell	MlPoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MnT4TY5pcWKrdHnvckBw\iCqdX3hckBGWzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|LkW5JI5O	M1npUnNCVkeHUh?=
H-EMC-SS cell	NFLYTWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3jJcWlvcGmkaYTpc44hd2ZiaIXtZY4hUC2HTVOtV3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N	Ml7TV2FPT0WU
NCI-H1703 cell	M1rxOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MVTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUewN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjhibl2=	MULTRW5ITVJ?
BHT-101 cell	NWfOTJFoT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Ml;ZTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44OiCwTR?=	Mn\tV2FPT0WU
SK-OV-3 cell	NVvF[\|dGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MUTJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU:YLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlc2KG6P	NIn2PIlUSU6JRWK=
EW-24 cell	NHv1OWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NY\1N\|M4UW6qaXLpeIlwdiCxZjDoeY1idiCHVz2yOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDNibl2=	NFTpV4lUSU6JRWK=
PSN1 cell	Mn;4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MnXLTY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz64OEBvVQ>?	NGrMe3JUSU6JRWK=
OVCAR-8 cell	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MljRTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj24JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{46QSCwTR?=	NIDydYlUSU6JRWK=
NCI-H1563 cell	MknMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M4TDO2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zMzDuUS=>	M3rMdHNCVkeHUh?=
SW756 cell	Mk\qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NUHXWWdbUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTNibl2=	NXSzRVhxW0GQR1XS
A375 cell	NF70eotIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NUCzT2Y2UW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yPCCwTR?=	MV\TRW5ITVJ?
Ca9-22 cell	MnX2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVXvPW9iUW6qaXLpeIlwdiCxZjDoeY1idiCFYUmtNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjJ3IH7N	M2naNnNCVkeHUh?=
SW1990 cell	MnG4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MojHTY5pcWKrdHnvckBw\iCqdX3hckBUXzF7OUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlMzKG6P	NFP0ellUSU6JRWK=
ES4 cell	NIPhSZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MYfJcohq[mm2aX;uJI9nKGi3bXHuJGVUPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwM{mgcm0>	MkWwV2FPT0WU
HCE-T cell	NYCwe2ZMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NEL3dXdKdmirYnn0bY9vKG:oIHj1cYFvKEiFRT3UJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PSCwTR?=	MnLGV2FPT0WU
MOLT-16 cell	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NEHVcplKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV\|IH7N	M4TTZ3NCVkeHUh?=
HSC-4 cell	NHXaSVNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MmK4TY5pcWKrdHnvckBw\iCqdX3hckBJW0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuPEBvVQ>?	M2jzNHNCVkeHUh?=
NCI-SNU-1 cell	M4XGTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1PNPWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC56NjDuUS=>	M3ny[nNCVkeHUh?=
EW-11 cell	M1HTS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGDvTJpKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46KG6P	M1nSbXNCVkeHUh?=
HT-1080 cell	M4TZdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NY[4T3luUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC57OTDuUS=>	NH7NfmZUSU6JRWK=
MES-SA/Dx5 cells	NEXSZZpEgXSxdH;4bYNqfHliYYPzZZk>	M1XUd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1GWy2VQT;EfFUh[2WubIOsJGlEPTB;NTDuUS=>	NFf5bWczOzl\|N{m4NS=>
SW1710 cell	M37BUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGXCV3ZKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTZibl2=	NEDvPXhUSU6JRWK=
EW-1 cell	M{PQUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MWLJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkK0JI5O	NXLHUnZJW0GQR1XS
BV-173 cell	NIjrenZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NV7Yd25MUW6qaXLpeIlwdiCxZjDoeY1idiCEVj2xO\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7IH7N	NV\3fohsW0GQR1XS
TE-8 cell	M2DrOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NUTBe5djUW6qaXLpeIlwdiCxZjDoeY1idiCWRT24JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41OSCwTR?=	MkC5V2FPT0WU
G-401 cell	M4fzV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NInHfW5KdmirYnn0bY9vKG:oIHj1cYFvKEdvNECxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41OyCwTR?=	Mn;GV2FPT0WU
KOSC-2 cell	NFzKWXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NH\SfG1KdmirYnn0bY9vKG:oIHj1cYFvKEuRU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDVibl2=	M3niR3NCVkeHUh?=
HuCCT1 cell	M3;EZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1HFXGlvcGmkaYTpc44hd2ZiaIXtZY4hUHWFQ2SxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42OiCwTR?=	M1n5cHNCVkeHUh?=
FADU cell	NWLlUZNvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M2fyVWlvcGmkaYTpc44hd2ZiaIXtZY4hTkGGVTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuOlYhdk1?	NHPDUWZUSU6JRWK=
MHH-ES-1 cell	MoLBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NWXhSIRCUW6qaXLpeIlwdiCxZjDoeY1idiCPSFitSXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwNkmgcm0>	NH;w[WRUSU6JRWK=
ES3 cell	NXrOZnZxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M{XNSWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT63PUBvVQ>?	MkP3V2FPT0WU
OVCAR-4 cell	M13zeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NXLSdmRjUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NzDuUS=>	MXvTRW5ITVJ?
HD-MY-Z cell	NULtdngyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFnEWHJKdmirYnn0bY9vKG:oIHj1cYFvKEiGLV3ZMXoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjlzIH7N	NWS2OoZsW0GQR1XS
human JAR cell	MlXoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MYfJcohq[mm2aX;uJI9nKGi3bXHuJGpCWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwOUegcm0>	M{m5NnNCVkeHUh?=
A427 cell	MoTHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXTJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkC3JI5O	NIHWcZVUSU6JRWK=
697 cell	MkPaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Mln5TY5pcWKrdHnvckBw\iCqdX3hckA3QTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkGzJI5O	NF3pZWVUSU6JRWK=
OVCAR-3 cell	M4rD[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NXW2TYl{UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5{IH7N	MUfTRW5ITVJ?
human NB14 cell	NVm1N4k{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFHHNG9KdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY1KG6P	MUfTRW5ITVJ?
GB-1 cell	M1TiSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Ml3ETY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nj63NUBvVQ>?	NYTjUXNUW0GQR1XS
COR-L105 cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MkD5TY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEGwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPzZibl2=	NHr3NFRUSU6JRWK=
647-V cell	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFziVXdKdmirYnn0bY9vKG:oIHj1cYFvKDZ2Nz3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok46KG6P	M17ENHNCVkeHUh?=
human K5 cell	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnnKTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdibl2=	NWrpWY52W0GQR1XS
DMS-273 cell	M3LhO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NEXkSFVKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N	MXXTRW5ITVJ?
UM-UC-3 cell	NFTSSXJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MWDJcohq[mm2aX;uJI9nKGi3bXHuJHVONVWFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA3KG6P	NILKZWRUSU6JRWK=
HEL cell	M4mwcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MUTJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdwMEigcm0>	NV7TUINNW0GQR1XS
human KU-19-19 cell	NUPnN\|VwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NX7ZS3FCUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdwMEmgcm0>	NXvOUIJ6W0GQR1XS
MC-IXC cell	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M172PGlvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4yPyCwTR?=	NEnUenFUSU6JRWK=
human H4 cell	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVLJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5{NTDuUS=>	M33KUnNCVkeHUh?=
NUGC-3 cell	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NVnUcppCUW6qaXLpeIlwdiCxZjDoeY1idiCQVVfDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjN\|IH7N	M3vySHNCVkeHUh?=
CHP-212 cell	NVzPV4h3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mn;rTY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{PCCwTR?=	NGT6[o9USU6JRWK=
human SW982 cell	NVrnTIdRT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFLLcGRKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{41PCCwTR?=	MoWzV2FPT0WU
C-33-A cell	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NYrEcWJFUW6qaXLpeIlwdiCxZjDoeY1idiCFLUOzMWEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV6IH7N	MYPTRW5ITVJ?
PC-3 cell	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M{LVW2lvcGmkaYTpc44hd2ZiaIXtZY4hWENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuPFkhdk1?	MV;TRW5ITVJ?
COLO-684 cell	M1jTeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NImyZ3RKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tOlg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QS5{MTDuUS=>	M{jlV3NCVkeHUh?=
SNU-387 cell	MnvSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MmezTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvM{i3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU41QSCwTR?=	MnfhV2FPT0WU
U251 cell	MonqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Moj0TY5pcWKrdHnvckBw\iCqdX3hckBWOjVzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;OT64OkBvVQ>?	M4TGNXNCVkeHUh?=
A673 cell	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NIW2[JpKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU43KG6P	NXKxNJVyW0GQR1XS
human T47D cell	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHXRdItKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOk44QSCwTR?=	M4Lxd3NCVkeHUh?=
A549 cell	NH\NT5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MlXuTY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUmuOkBvVQ>?	NW\DcZZHW0GQR1XS
PC-14 cell	NVPrbWhIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MWTJcohq[mm2aX;uJI9nKGi3bXHuJHBENTF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MkSuO\|Mhdk1?	NYrIVGFlW0GQR1XS
A704 cell	NV3NR\|FZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M3;Od2lvcGmkaYTpc44hd2ZiaIXtZY4hSTdyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUK3MlQ2KG6P	Mmf2V2FPT0WU
MCF7 cell	NILsZ\|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MnPxTY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;M{GuN\|Yhdk1?	M{PtV3NCVkeHUh?=
PC3 cells	MlHGSpVv[3Srb36gZZN{[Xl?	M4DxVGlvcGmkaYTpc44hd2ZiUFTLNU1u\WSrYYTl[EBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IGTodlMxQCC{ZYPp[JVmKGmwIHj1cYFvKFCFMzDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjFzMzFOwG0>	Mnr3NlE{PDF4N{W=
F-36P cells	MYHQdo9tcW[ncnH0bY9vKGG\|c3H5	Mk\jRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCILUO2VEBk\WyuczygTWM2OD1yLkK4JO69VQ>?	NEXqbWIzOTN2MU[3OS=>
OCI-AML2 cells	M1znVnBzd2yrZnXyZZRqd25iYYPzZZk>	M3XKTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT1PJMWFOVDJiY3XscJMtKEmFNUC9NE4{PSEQvF2=	NGOwN3czOTN2MU[3OS=>
K562 cells	MVzQdo9tcW[ncnH0bY9vKGG\|c3H5	NYnkRodpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUG4JO69VQ>?	MkLmNlE{PDF4N{W=

... Click to View More Cell Line Experimental Data

In vivo

Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. ^[4]

Protocol

Cell Research:^[1]	+ Expand Cell lines: Hs294T, HSB2, and Ramos Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM Incubation Time: 18, or 24 hours Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit. (Only for Reference)
Animal Research:^[4]	+ Expand Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors Formulation: Dissolved in DMSO, and diluted in saline Dosages: ~100 mg/kg Administration: Intravenous injection (Only for Reference)

Cell Research:^[1]

+ Expand

Cell lines: Hs294T, HSB2, and Ramos
Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
Incubation Time: 18, or 24 hours
Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
(Only for Reference)

Animal Research:^[4]

+ Expand

Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
Formulation: Dissolved in DMSO, and diluted in saline
Dosages: ~100 mg/kg
Administration: Intravenous injection
(Only for Reference)

References

[4] Gehrmann M. Curr Opin Investig Drugs, 2006, 7(6), 574-580.

+ Expand

Solubility (25°C)

In vitro	DMSO	80 mg/mL (199.75 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Elesclomol (STA-4783) SDF

Molecular Weight	400.5
Formula	C₁₉H₂₀N₄O₂S₂
CAS No.	488832-69-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can we use the compound for in vivo mouse studies?
Answer:
S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Features:Displays very low toxicity toward normal cells.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Elesclomol (STA-4783)

Cited by 7 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Elesclomol (STA-4783) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Choose Your Country or Region

By Signaling Pathways

By product type

Elesclomol (STA-4783)

Cited by 7 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Elesclomol (STA-4783) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)